Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | Chief Medical Officer | September 06, 2019 | September 10, 2019 |
| Trevi Therapeutics, Inc.TRVI · Entity 4387 | Chief Medical Officer | February 15, 2024 | February 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aldeyra Therapeutics, Inc.
Report date September 06, 2019 · Filed September 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,878 |
Reported balance
After 2019-09-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-09-06 · Purchase · Acquired 5,000 · Balance 17,878 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: Includes 1,366 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2: Includes 1,366 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in 2019.
Trevi Therapeutics, Inc.
Report date February 15, 2024 · Filed February 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2034-02-14 | Direct | 175,000 |
Reported balance
After 2024-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-15 · Grant · Acquired 175,000 · Balance 175,000 F1: This option was granted on February 15, 2024. The 175,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 15, 2025 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 15, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 15, 2024. The 175,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 15, 2025 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 15, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2024 Filed Feb 16, 2024 21:43 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0000950170-24-016464 · ownership.xml · derivative · entry 1 Clark David J · CIK 0001662693 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2034-02-14 F1 · derivative.exercise_date: This option was granted on February 15, 2024. The 175,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 15, 2025 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 15, 2028. Read SEC document |
| November 14, 2022 Filed Nov 14, 2022 21:43 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001209191-22-056635 · doc4.xml · derivative · entry 1 Clark David J · CIK 0001662693 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-11-13 F1 · derivative.exercise_date: This option was granted on November 14, 2022. The 300,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on November 14, 2023 and as to the remaining 75% of the shares in equal monthly installments thereafter, through November 14, 2026. Read SEC document |
| September 06, 2019 Filed Sep 10, 2019 21:01 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | PurchaseCommon Stock | 5,000 | $5.06 | $25,311.00 |
DisclosureSEC source: 0000899243-19-023265 · doc4.xml · nonDerivative · entry 1 Clark David J · CIK 0001662693 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,878 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 1,366 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in 2019. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 22:22 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0000899243-19-006730 · doc4.xml · derivative · entry 2 Clark David J · CIK 0001662693 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-03-04 F3 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2019. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 22:22 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantCommon Stock | 3,503 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006730 · doc4.xml · nonDerivative · entry 1 Clark David J · CIK 0001662693 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,512 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. F2 · balance_after: Includes 3,235 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in 2018. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:40 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 108,633 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0000899243-18-006818 · doc4.xml · derivative · entry 2 Clark David J · CIK 0001662693 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,633 Underlying: Common Stock · 108,633 shares Expires 2028-03-05 F3 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2018. Read SEC document |
| December 29, 2017 Filed Mar 8, 2018 21:40 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantCommon Stock | 4,774 | $4.00 | $19,072.13 |
DisclosureSEC source: 0000899243-18-006818 · doc4.xml · nonDerivative · entry 1 Clark David J · CIK 0001662693 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,774 F1 · date: Represents the voluntary reporting of 4,774 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in December 2017. F1 · shares: Represents the voluntary reporting of 4,774 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in December 2017. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 3, 2017. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 22:45 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 155,656 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0000899243-17-006713 · doc4.xml · derivative · entry 1 Clark David J · CIK 0001662693 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,656 Underlying: Common Stock · 155,656 shares Expires 2027-03-02 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.